Comprehensive Opioid, Stimulant, and Other Substances Use Program — CFDA 16.838

COSSUP obligations at $774,298,797.93

USAspending.gov records $774,298,797.93 in obligations under CFDA 16.838. Four hundred fifty-six awards produce that stock. A simple average is about $1,698,024 per award. That average is a quotient of two packet totals, not a typical local-project budget and not a cost per patient. Other Bureau of Justice Assistance substance-use listings tagged under different CFDA numbers are not mixed into the $774,298,797.93.

The assistance-listing title is COMPREHENSIVE OPIOID, STIMULANT, AND OTHER SUBSTANCES USE PROGRAM. CFDA 16.838 is the identifier. Combining 16.838 with Byrne JAG or residential-substance-abuse codes would invent a combined justice-and-treatment total this packet does not contain. Read the $774,298,797.93 as the obligation book tagged 16.838 only.

360 recipients on 456 award rows

Three hundred sixty recipients share 456 awards, or about 1.3 award records per recipient on average. Splitting $774,298,797.93 evenly would assign about $2.15 million per recipient. That density is a competitive-local-government pattern: most named jurisdictions and partners carry a single assistance row. The packet does not list the 360.

Fifty-three jurisdictions in the geographic count cover states plus a few extra coded entities. COSSUP dollars follow funded applicants, not equal shares. Place-of-performance amounts are on the program table. Recipient count is organizational, not a census of treatment providers or first responders.

Award rows are not an overdose census

Among Justice listings, 16.838 is a mid-row competitive file: 456 awards against 360 recipients. Award count is a weak proxy for “number of COSSUP sites” and a worse proxy for people treated. Recipients (360) tell you how many named organizations sit on the extract; awards (456) tell you how many assistance rows were stored.

The packet does not report overdose deaths, MAT enrollments, or diversion cases. Citing 456 as treatment slots would be a unit error. Keep the units straight: dollars, awards, recipients, jurisdictions. The $774,298,797.93 stock is the obligation figure from USAspending.gov.

Obligations versus COSSUP outlays

The $774,298,797.93 is an obligation total from USAspending.gov. Outlays — cash paid against Comprehensive Opioid, Stimulant, and Other Substances Use Program awards — are not in the packet. A competitive file can show a large obligation stock while sites draw across project periods. Deobligations and upward adjustments both move the total.

Use CFDA 16.838 to size this substance-use listing in the assistance file. Do not use it as a mortality dashboard. Those series live elsewhere. This page reports the obligation book tagged 16.838.

What the 16.838 tables omit

The program hub lists award-backed obligations from USAspending.gov. It is not a treatment-capacity file, not a coroner extract, and not a naloxone-distribution log. Series that never appear as assistance awards will not show up in the $774,298,797.93. That omission is definitional rather than a gap in the 456 award rows.

Place-of-performance on 53 jurisdictions is a coding field. Read the program page before treating those cells as equal shares of opioid-response funding. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already paid to local grantees.

Where the 16.838 table lives

The program page overlays these four facts. The all-programs index ranks 16.838 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other Justice listings. For 16.838 only, start on the program page.

CFDA 16.838’s 456 awards spread $774,298,797.93 across 360 recipients and 53 jurisdictions. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 1.3 award records per recipient is the density story. Outlays remain a separate column. Source: USAspending.gov assistance awards.

A researcher comparing 16.838 with Byrne JAG or residential-substance-abuse codes should keep CFDA numbers separate. The 360-recipient headcount on 456 awards is a near 1:1 competitive-project fingerprint spanning 53 jurisdictions. Quote $774,298,797.93 as the USAspending obligation stock for the Comprehensive Opioid, Stimulant, and Other Substances Use Program only. Overdose deaths, treatment slots, and naloxone kits remain outside the packet. Outlays are a separate column.

Questions

How much is obligated for the comprehensive opioid and stimulant program?

USAspending.gov records $774,298,797.93 in obligations for CFDA 16.838. SpendingVault indexes 456 awards, 360 recipients, and 53 jurisdictions. The figure is an obligation sum from assistance awards, not an outlay and not an overdose count. CFDA 16.838’s $774,298,797.93 is the USAspending obligation stock.

How many awards does CFDA 16.838 carry?

The listing shows 456 awards against 360 recipients, or about 1.3 award records per recipient. A simple average is about $1,698,024 per award. Award count is not a count of treatment slots or kits distributed. Recipient dollars are on the program page.

How many organizations receive 16.838 awards?

The extract lists 360 recipients. Those are organizational recipients on assistance awards tagged 16.838, not a census of treatment providers. Geographic coding covers 53 jurisdictions. The packet does not name the 360 or publish mortality figures. The packet reports obligations from USAspending.gov, not outlays.

Is $774,298,797.93 already paid for COSSUP grants?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 16.838’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn, remaining balances, or overdoses averted. The $774,298,797.93 on 456 awards is the obligation figure. The packet reports obligations from USAspending.gov, not outlays.